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Abstract PurposeThepurposewastoestablishtheimpact
on survival of early detection of a local recurrence of breast
cancer as compared to late detection. Design A meta-anal-
ysis was carried out using Cochrane review manager
software (RevMan version 4.2). Studies were included if
women were treated for primary breast cancer without evi-
dence of distant metastasis at primary diagnosis and if these
concerned routine follow-up strategies focusing on the early
detection of curable recurrences. Data regarding the risk for
deathwerederivedfromeachstudy.Multilevelmodelswere
used to study heterogeneity by using MLWin. Results Thir-
teen studies concerning 2,263 patients were included. Early
detectionofbreastcancerrecurrencesduringfollow-upgave
a signiﬁcantly better survival as compared to late detected
recurrences (HR: 1.68 (95% CI: 1.48–1.91)). Survival was
better when the recurrence was found by mammography
instead of physical examination or in patients without
symptoms as compared to those with symptoms (HR: 2.44
(95% CI: 1.78–3.35); HR: 1.56 (95% CI: 1.36–1.79),
respectively). If all breast cancer recurrences would be
detectedearlier,that5–8deaths(i.e.anabsolutereductionin
mortality of 17–28%) would be avoided by performing
routine follow-up during a 10 year-period for 1,000 breast
cancer patients. Conclusion These data support the hypoth-
esis that detection of isolated loco-regional or contra-lateral
breast cancer recurrences in patients without symptoms has
beneﬁcial impact on survival of breast cancer patients when
compared to late symptomatic detection.
Keywords Breast neoplasm   Survival   Recurrence  
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Introduction
Screening for breast cancer has resulted in increasing
numbers of patients diagnosed with early breast cancer.
The combined effect of early diagnosis and improved
treatment for breast cancer has led to a signiﬁcant decrease
in breast cancer-related mortality. As a consequence, the
prevalence of breast cancer survivors rises. After curative
treatment for breast cancer it is common practice to enter
patients in a surveillance program for many years. There
will be more breast cancer survivors followed by more
need for long-term surveillance [1]. At the same time, there
is an increasing pressure on breast services from new
referrals and urgent cases [2]. It is predicted that there will
be a 48% increased need for cancer services by 2020. This
puts an increasing burden on follow-up oncology clinics
[3]. There is a need to quantify the beneﬁts of follow-up to
organise the follow-up more efﬁciently.
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DOI 10.1007/s10549-008-0023-4One of the important goals of surveillance is improve-
ment of survival. The surveillance program can extend
survival when two assumptions are made: (1) most recur-
rences are detected at an early stage (i.e. are without
symptoms at diagnosis) during the surveillance visits and
(2) the early treatment of recurrences leads to better sur-
vival [4]. About 40% of loco-regional recurrences were
asymptomatic at diagnosis in an earlier systemic review
and meta-analysis that involved 5,045 patients and 378
isolated loco-regional recurrences [5]. The risk of breast
carcinoma-related death is increased for patients with a
local recurrence compared to those without local recur-
rence [6, 7]. Still, the effect of early detection of curable
recurrence on overall survival remains questionable and
controversy remains on the beneﬁts of regular follow-up
[8]. The aim of this study is to perform a meta-analysis of
the impact of early detection of loco-regional or contra-
lateral breast cancer recurrence on survival.
Methods
Search strategy
PubmedMedline,CancerLit,Cochrane,Webofsciencesand
Embase were searched for relevant studies. Studies in any
language were examined published between 1966 and 2006.
MESH words used were ‘‘Breast Neoplasms’’, ‘‘Follow-Up
Studies’’, ‘‘Mammography’’, ‘‘Physical Examination’’ and
‘‘Survival’’. Title and abstract were searched for the words:
‘‘breast cancer’’, ‘‘follow-up’’, ‘‘detection’’, ‘‘survival’’ and
‘‘recurrence’’. Reference lists and reviews were searched
by hand.
Selection of papers
Studies were included in the meta-analysis when they met
the following inclusion criteria. Target population: Studies
were included if women were treated for primary breast
cancer without evidence of distant metastasis at primary
diagnosis. Follow-up: Studies were included if they con-
cerned routine follow-up strategies or tests focusing on
the early detection of curable recurrence (loco-regional
recurrence and contralateral recurrence). Contrast: Studies
were included if they focused on comparing early detec-
tion (recurrences without symptoms) versus late detection
(recurrences with symptoms). Outcome: Studies were inclu-
ded when they presented survival data. Data presentation:
Studies were included when they presented hazard ratios
expressing the risk of death or when they presented
information for calculating these hazard ratios (number of
deaths and exact p-values).
Two researchers (GHdeB and LWL) independently
examined titles (n = 1,369) and abstracts (n = 413) to
decide if the full text articles should be obtained. Cases of
disagreement were resolved by discussing the titles and
abstracts (n = 14). Six studies fulﬁlled the inclusion cri-
teria regarding follow-up, contrast and outcome, but did
not present hazard ratios or information for calculating
these hazard ratios. For two of these six studies, the number
of deaths among the patients with recurrences was not
available [9, 10]. For two studies, no (exact) P-value was
available [11, 12]. For two studies, the number of deaths
among the patients with recurrences was not available, nor
the (exact) P-value was available [13, 14]. As a conse-
quence 13 of 68 full-text articles that were examined could
be included in the analysis. For an overview of studies
included in the analysis, see Table 1.
Data extraction and deﬁnition
Data were extracted independently by the two researchers
(GHdeB and LWL), by means of a predeﬁned form. For an
overview of the topics, see Table 1. Loco-regional recur-
rences were deﬁned as the presence of cancer in the breast
or axilla on the same side. Contra-lateral recurrences were
deﬁned as cancer in the other breast after the primary
treatment of the ﬁrst breast cancer. Distant metastases were
deﬁned as the evidence of breast cancer in any part of the
body except breast and axilla. It was registered whether
follow-up time was measured from the time of primary
treatment or from the time of recurrence. A follow-up
scheme was considered as standard when patients received
regular mammography with or without physical examina-
tion. A follow-up scheme was considered as intensive
when patients received additional blood tests and bone
scans regularly and independent of symptoms. A recur-
rence was considered as being detected early when it was
mammographically detected during a routine clinic visit in
a patient without symptoms. A recurrence was considered
as being detected late when it was detected by patient
themselves.
Assessment of methodological quality and publication
bias
Methodological quality was assessed independently by the
investigators (GHdeB and LWL) by means of a predeﬁned
form. Because there is no generally accepted standard for
measuring methodological quality in prognostic studies,
this form was derived from the work of Altman and
Laupacis and is presented in Table 2 [15, 16]. A score six
or of higher was considered as a high quality score. The
cut-off point was based on the median.
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123To investigate publication bias, in Fig. 1 studies are
presented based on sample size to get an impression of a
potential relationship between sample size and effect size.
To quantify this relation, Kendall’s tau coefﬁcient was
calculated [17]. To estimate whether publication bias is
likely to be a problem in this meta-analysis, the fail-safe
number was assessed to calculate how many studies are
needed to counterbalance the results [18].
Statistical analysis
The main outcome in this analysis was the hazard ratio
(HR) and its standard error (SE). If these data were not
directly available, these were estimated based on the total
number of events in both groups and the two-sided P-value
by using the method described by Parmar [19]. Based on
the SE, 95% conﬁdence intervals (CIs) were calculated.
HRs were directly presented in only one study [20].
In the next step, HRs were combined by using Review
ManagerVersion4.2.ByusingtheGenericInverseVariance
method, logHRs and SErs were entered. The pooled result
was expressed as combined HRs with ﬁxed effects with a
95% CI, and an overall test on heterogeneity was performed
using the Chi-square test. Despite non signiﬁcant results, we
still explored heterogeneity because of the small number of
studies. The following potential sources of heterogeneity
were explored: the type of recurrences considered, the
starting point for computation of follow-up time, type of
follow-up scheme, comparisons made, quality score, and
type of outcome. For each potential source of heterogeneity,
a multilevel model was developed with the logHR as
dependentvariableandthesourceofheterogeneityaswellas
the SE as independent variables. To quantify the theoretical
extent of survival improvement, if the loco-regional or
contra-lateral recurrence would be early detected, the
population attributable risk was calculated [21].
Results
Study characteristics
In the analysis, 2,263 patients from 13 studies were
included having 724 loco-regional recurrences, 627 contra-
lateral recurrences, 459 distant metastases, 30 loco-regio-
nal recurrences with distant metastases combined and 423
not speciﬁed recurrences (see Table 1). Fifty-eight percent
(1,223) of these patients had a recurrence detected early
and 42% were with late detection. The included studies
were comparable regarding the distribution of age, primary
tumour stage and primary surgical treatment. In the
majority of studies, the time of follow-up was measured
from date of primary diagnosis (n = 10; 77 %). In seven
studies (54%) patients were offered routine follow-up,
including regular mammography and physical examina-
tion, and in six studies patients were offered intensive
follow-up including routine additional tests. Seven studies
(54%) focused on patients diagnosed with recurrences
without symptoms as compared to patients diagnosed with
recurrences with symptoms. One study focused on recur-
rences found during routine follow-up or outside routine
follow-up. Five studies focused on recurrences diagnosed
by mammography or symptoms. Eleven studies had death
as primary outcome, and two studies had a mixed outcome
(death of distant metastases).
Quality score and publication bias
Seven studies had a quality score of 5 or lower (Table 2).
There were no indications of publication bias because
increasing sample size was not related to increasing effect
size (Kendall’s tau coefﬁcient: -0.194 (P = 0.36)). The
fail-safe number was 210, which means 210 contrary
 Hazard  Ratio  (fixed)  Hazard  Ratio  (fixed)
log[Hazard Ratio] (SE)  95%  CI  95%  CI
Ciatto S
Kaas R
Te Boekhorst S
Voogd AC
Tomin R
Perrone MA
Kindler M
Stierer M
Doyle T
Orel SG
Imoto S
Wagman LD
Hussain ST
 0.1  0.2  0.5  1  2  5  10
Studies
Total (95% CI)
Test for heterogeneity: Chi square= 13.02, df = 12 (P = 0.37),
Test for overall effect: Z = 7.93 (P < 0.00001)
Early detected Late detected
Sample
Size
Fig. 1 Impact on survival of
early detection of recurrences
after the primary treatment for
breast cancer. Note: Early
detected recurrences versus late
detected recurrences
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123studies would need to be included to counterbalance the
result in this meta-analysis at a signiﬁcance level 0.05.
Survival
Overall, survival was signiﬁcantly better with early detection
oftherecurrence(HR:1.68(95%CI:1.48–1.91,P\0.0001;
see Fig. 1).Inall 13studies,the HRshoweda trend forbetter
survival with early detection, but ﬁve out of the 13 included
studiespresentednosigniﬁcantresult(Table 3).Therewasno
signiﬁcant heterogeneity among the studies (Chi-square =
13.12, P = 0.37; Fig. 1).
The chance of beneﬁt of early detection was statistically
signiﬁcant higher in the studies that presented the data
regarding loco-regional recurrence and contra-lateral
recurrence separately from distant metastases (HR: 2.55
(95% CI: 1.76–3.70) as compared to the studies that did not
(HR: 1.59 (95% CI: 1.38–1.82; P = 0.02); see Table 4).
Table 3 Outcomes in the papers that met the inclusion criteria
Author Time of follow-up Number of death among
early detected patients
Number of death among
late detected patients
Log-rank
P-value
HR SE
Ciatto S, 2004/1990 1–31 years -/234 -/105 0.008 2.0408 0.7301
Imoto S, 1998 Median: 878 days (196–1806) 14.57/304 17.25/354 0.48 1.2865 0.3556
Kindler M, 1989 - 109/1214 54/544 0.2 1.2652 0.1696
Perrone MA, 2004 Median: 94.7 month (9.7–198.3) 87/101 80/110 0.001 1.6656 0.1549
Stierer M, 1989 Median:41 month 8/374 26/564 0.1105 1.7705 0.3504
Te Boekhorst S, 2001 0–16 years 153/170 81/100 0.0003 1.6599 0.1354
Tomin R, 1987 0–16 years 67/894 143/1594 0.0017 1.6010 0.1439
Wagman LD, 1991 5 years+ 26/264 24/384 0.009 2.1505 0.2879
Doyle T, 2001 0–20 years 11/42 4/47 0.06 2.6493 0.5172
Hussain ST, 1995 0–11years 14/28 0/5 0.03 9.5421 0.7454
Kaas R, 2001 Median:82.5(10–166) 51/166 16/109 0.015 3.0320 0.4461
Orel SG, 1993 0–13 years 6/38 2/34 0.28 2.1517 0.7082
Voogd AC, 1999 2–4 years 61/141 10/47 0.02 2.0881 0.2741
4 Estimated from survival curve
Table 4 Comparison of HRs
for six sources of heterogeneity
a Assessed clinically, during
interval or routine visit
b Based on estimations of the
multilevel model
Sources of heterogeneity Number of
studies
Combined HR 95% CI P-value
b
Type of recurrence
Only loco-regional or contra-lateral recurrences 6 2.55 1.76–3.70
LRR, CLR and DM 7 1.59 1.38–1.82 0.02
Starting point for computation of follow-up time
Primary treatment 9 1.64 1.41–1.91
Recurrence 3 1.77 1.39–2.25 0.62
Type of follow-up scheme
Standard 7 1.92 1.55–2.38
Intensive 6 1.56 1.33–1.83 0.12
Comparison made
Patient reported symptoms (no versus yes) 7 1.56 1.36–1.79
Mammographically only versus clinically assessed
a 6 2.44 1.78–3.35 0.01
Quality scores
[5 6 1.73 1.45–2.06
B5 7 1.81 1.45–2.27 0.61
Type of outcome
Death or distant metastases 2 2.20 1.37–3.54
Death 11 1.64 1.44–1.88 0.24
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123When analyzing the studies that calculated follow-up time
from the date of primary treatment separately from the
studies that calculated follow-up time from the date of
recurrences, we observed that the HR for the studies
excluding lead-time bias were comparable for the studies
that calculated time to follow-up from the date of recur-
rence. (HR: 1.64 (95% CI: 1.41–1.91), HR: 1.77 (95% CI:
1.39–2.25), respectively). Studies focusing on the impact of
an intensive regimen for follow-up gave a HR for survival
comparable to studies focusing on a standard regimen
for follow-up (HR: 1.56 (95% CI: 1.33–1.83), HR: 1.92
(95% CI: 1.55–2.38), respectively; P = 0.12). Recurrences
assessed in patients without symptoms were related to a
higher probability of survival than when symptoms were
present (HR: 1.56 (95% CI: 1.36–1.79)). Survival was
better in studies where recurrences were found by mam-
mography instead of studies where recurrences were being
assessed clinically (HR: 2.44 (95% CI: 1.78–3.35)). This
advantage is signiﬁcantly higher for studies mammo-
graphically assessed than for tumours clinically assessed
(P = 0.01). Studies with a higher quality score were not
related to a different HR than studies with a lower quality
score (HR: 1.73 (95% CI: 1.45–2.06), HR: 1.81 (95% CI:
1.45–2.27), respectively; P = 0.61). Studies focusing on
death or distant metastases had a non-signiﬁcant higher HR
for survival than studies focussing on death only (HR: 2.20
(95% CI: 1.37–3.54), HR: 1.64 (95% CI: 1.44–1.88),
respectively; P = 0.24).
Absolute effects
There would be an absolute reduction in mortality of
17–28% of breast cancer patients with recurrences, if all
recurrences would be early detected, given the pooled HR
of 1.68 (95% CI: 1.48 to 1.91) and the proportion of the
early detected recurrences (40%) [5]. Given the fact that
nowadays nearly all patients in Western countries are in
follow-up, the incidence of recurrence (10%) during a
10 year-period and the survival rate at 10 years (70%) of
breast cancer patients with recurrence [22], 5–8 deaths
would be avoided by performing routine follow-up during a
10 year-period for 1,000 breast cancer patients.
Discussion
This meta-analysis shows that early detection of isolated
recurrences in patients without symptoms by routine
follow-up or mammography improves survival of patients
with breast cancer recurrences (HR = 1.68; 95% CI:
1.48–1.91). Given the proportion of early detected loco-
regional recurrences is 40%, there would be an absolute
reduction in mortality of 17–28% of breast cancer patients
with recurrences, if all loco-regional recurrences would be
detected early. Individual studies have been inconclusive in
answering the question whether early detection of breast
cancer recurrences is related to longer life. Five studies
included did not show a signiﬁcant difference in improving
survival between early detection versus late detection of
loco-regional recurrence [23–27]. One explanation might
be that these studies had too small sample sizes. The meta-
analysis allowed us to include the observations of more
than 2,000 patients, and yields a far more precise estimate
of the effect on survival of early detection of loco-regional
or contra-lateral breast cancer recurrences.
A topic of debate in follow-up of breast cancer is the
role of mammography and physical examination. Several
studies concluded that the early detection of local disease
recurrence require both clinical examination and mam-
mography [28–30]. One study reported that the tumour size
of local recurrences detected by mammography alone were
smaller than those detected by physical examination [29].
Several studies [20, 31, 32] suggested that breast cancer
patients who received regular mammograms were less
likely to die than breast cancer patients who did not, and
that recurrences found by mammography are associated
with a better survival [33, 34]. A similar effect was seen in
this meta-analysis. Our ﬁndings suggested that survival is
better when the recurrence is found by mammography
instead of physical examination (HR: 2.44 (95% CI: 1.78–
3.35)). There were insufﬁcient data to study the contribu-
tion of yearly mammogram as compared to 6 month
mammogram. In this meta-analysis, late detected recur-
rences included those recurrences detected by breast self-
examination or by symptoms. Recurrences assessed in
patients without symptoms are also related to a higher
probability of survival than when symptoms are present
(HR: 1.56 (95% CI: 1.36–1.79)). This advantage is higher
for tumours assessed by mammography (P = 0.01). These
ﬁndings indicate that the actual survival beneﬁt of early
detection of a local recurrence by mammography may be
higher than the pooled overall data reported in this meta-
analysis. In the absence of related studies, the contribution
of breast self-examination is not clear. According to the
favorable effect size of early detection of curable recur-
rence by mammography, the result is in line with ASCO
guideline that women should be made aware that monthly
BSE does not replace mammography as a breast cancer
screening tool to early detect isolated breast recurrences
after a primary treatment for breast cancer [35].
In this meta-analysis, some studies were included that
did not present data for loco-regional recurrence and
contralateral recurrence separately from distant metastases,
although the primary focus was loco-regional recurrence or
contralateral recurrence [8, 24–26, 36, 37]. We found that
the chance of beneﬁt of early detection is signiﬁcantly
410 Breast Cancer Res Treat (2009) 114:403–412
123higher in the studies that presented the data regarding loco-
regional recurrence and contralateral recurrence separately
from distant metastases (HR: 2.55 (95% CI: 1.76–3.70) as
compared to the studies that did not (HR: 1.59 (95% CI:
1.38–1.82; P = 0.02)). The combined HR was attenuated
in the studies which included distant metastasis because the
early detection of distant metastasis unlikely had beneﬁt on
survival [38, 39].These ﬁndings may indicate that the
actual survival beneﬁt of early detection of a local recur-
rence is even higher than found in this meta-analysis.
There was no statistically signiﬁcant difference in HR
for survival between studies in this meta-anlaysis that used
an intensive regimen compared to a standard regimen for
follow-up (HR: 1.92 (95% CI: 1.55–2.38; HR: 1.56 (95%
CI: 1.33–1.83), respectively). This is in line with previous
publications in which it is found that intensive follow-up
schemes focusing on the early detection of distant metas-
tases does not improve the chances of survival [38, 39].
Lead time bias may have inﬂuenced the outcome of an
analysis like we did [37, 40]. Lead time bias means that
patients with disease detected by early diagnosis survive
longer than those whose disease is detected on the occur-
rence of new signs or symptoms, even when treatment is
without effect. When analyzing the ten studies that calcu-
lated follow-up time from the date of primary treatment
separately from the three studies that calculated follow-up
time from the date of recurrences we observed that the HR
for the studies excluding lead-time bias is comparable with
the HR for the studies that calculated time to follow-up
from the date of recurrence. (HR: 1.64 (95% CI: 1.41–
1.91), HR: 1.77 (95% CI: 1.39–2.25, respectively). Studies
focusing on death or distant metastases had a non-signiﬁ-
cant higher HR for survival than studies focussing on death
only (HR: 2.20 (95% CI: 1.37–3.54), HR: 1.64 (95% CI:
1.44–1.88), respectively; P = 0.24). This means that in this
analysis, the effect of lead-time bias does not explain the
effect of early detection that we found.
Studies with a higher quality score were not related to
better outcome than studies with a lower quality score (HR:
1.73 (95% CI: 1.45–2.06), HR: 1.81 (95% CI: 1.45–2.27),
respectively; P = 0.24). Identical beneﬁts were presented in
studies with high quality scores and studies with low quality
scores. Increasing sample size was not related to increasing
effects size (Kendall’s tau coefﬁcient: -0.194 (P = 0.36)).
Thefail-safenumberof210indicatesthat210contrarystudies
would be needed to counterbalance the result in this meta-
analysisatasigniﬁcancelevel0.05.Soevenifpublicationbias
existed, it is not a problem that weakened the results of this
meta-analysis.
A limitation of this meta-analysis is that all included
studies were retrospective. The optimal design would be a
clinical trial in which patients are randomized to follow-up
versus no-follow-up. Such a study is not feasible for ethical
and psychological reasons. Besides the early detection of
recurrence, there are many other factors that have impact
on breast cancer patients’ survival. Due to the incomplete
information on some important prognostic factors like age
of the women, tumour stages or surgical treatment, we
were not able to analyze the impact of these factors on the
survival related to early detection of recurrences.
These data support the hypothesis that detection of
breast cancer loco-regional or contra-lateral recurrences in
asymptomatic patients during routine follow-up or assessed
by mammography improves survival, when compared to
late symptomatic detection and give an indication of the
absolute effect. Further studies should focus on improve-
ment of follow-up strategies aiming at early detection of
loco-regional or contra-lateral recurrences and on cost-
effectiveness of these strategies.
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